Review article: moving towards common therapeutic goals in Crohn's disease and rheumatoid arthritis.
Fiche publication
Date publication
avril 2017
Journal
Alimentary pharmacology & therapeutics
Auteurs
Membres identifiés du Cancéropôle Est :
Pr JOUZEAU Jean-Yves
Tous les auteurs :
Allen PB, Olivera P, Emery P, Moulin D, Jouzeau JY, Netter P, Danese S, Feagan B, Sandborn WJ, Peyrin-Biroulet L
Lien Pubmed
Résumé
Crohn's disease (CD) and rheumatoid arthritis are chronic, progressive and disabling conditions that frequently lead to structural tissue damage. Based on strategies originally developed for rheumatoid arthritis, the treatment goal for CD has recently moved from exclusively controlling symptoms to both clinical remission and complete mucosal healing (deep remission), with the final aim of preventing bowel damage and disability.
Mots clés
Antibodies, Monoclonal, Humanized, therapeutic use, Arthritis, Rheumatoid, drug therapy, Crohn Disease, drug therapy, Disease Progression, Goals, Humans, Patient Care Planning, trends, Prospective Studies, Ustekinumab, therapeutic use
Référence
Aliment. Pharmacol. Ther.. 2017 Apr;45(8):1058-1072